Form 8-K - Current report:
SEC Accession No. 0001437749-25-020321
Filing Date
2025-06-13
Accepted
2025-06-13 16:07:53
Documents
13
Period of Report
2025-06-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20250612_8k.htm   iXBRL 8-K 46119
  Complete submission text file 0001437749-25-020321.txt   176956

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20250611.xsd EX-101.SCH 3579
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20250611_def.xml EX-101.DEF 11424
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20250611_lab.xml EX-101.LAB 15310
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20250611_pre.xml EX-101.PRE 11584
15 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20250612_8k_htm.xml XML 2874
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 251046568
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)